New combo therapy for colorectal cancer shows promise in early study
NCT ID NCT06557668
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at the medical records of 250 adults with colorectal cancer to see if adding an immunomodulator to standard cancer treatments helps them live longer. The goal is to compare survival and tumor response between those who got the immunomodulator and those who did not. No new treatments are given—just an analysis of past data.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chung-Shan Medical University Hospital
NOT_YET_RECRUITINGTaichung, Taiwan
-
Taichung Veterans General Hospital
RECRUITINGTaichung, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?